TCRT Q3'26 Earnings: EPS estimate is (2.05) USD
Alaunos Therapeutics (TCRT) will report Q3'26 earnings on November 17. Analysts expect an EPS of -2.05 USD. Revenue figures will also be disclosed.
Alaunos Therapeutics, Inc.
Alaunos Therapeutics is a preclinical-stage biopharmaceutical company developing orally administered small-molecule treatments for obesity and related metabolic disorders, including metabolic dysfunction-associated steatotic liver disease. Its lead candidate, ALN1003, is being studied in preclinical obesity models. The program uses a non-hormonal, non-incretin approach. Alaunos outsources production of the candidate’s active pharmaceutical ingredient and drug product to contract development and manufacturing organizations. It has not generated product revenue. Alaunos previously developed TCR-T cell therapies for solid tumors, but discontinued clinical development of those programs in August 2023. It retains related intellectual property. The company has one full-time employee and relies on consultants and external advisers for key functions. Its principal executive offices are in Fort Lauderdale, Florida.
No SEC Form 4 filings for $TCRT in the last 30 days.
See all $TCRT insider activity →Alaunos Therapeutics (TCRT) will report Q3'26 earnings on November 17. Analysts expect an EPS of -2.05 USD. Revenue figures will also be disclosed.
Alaunos Therapeutics (TCRT) regained compliance with Nasdaq's $2.5M stockholders' equity requirement, avoiding delisting. The company completed a private placement financing on October 14, 2026, which Nasdaq confirmed restored compliance. The delisting hearing scheduled for November 10, 2026, was canceled. Alaunos still faces risks related to equity, stockholder approvals, and future compliance.
Alaunos Therapeutics, Inc. (TCRT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in comp
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TCRT (Alaunos Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent TCRT coverage spans corporate actions, mergers & acquisitions and earnings.
Investors will gauge the actual results against the forecast; a miss could pressure the stock, while a beat may lift it.
Removal of delisting risk should support the stock.
The resolution removes a near-term delisting risk, likely supporting the share price.
Fairmount’s near-20% stake and board-designation rights can materially shift Alaunos governance, influencing strategy and post-merger execution risk.
Deal plus large concurrent funding likely supports upside momentum, but also raises dilution and execution risk around early-stage PAH assets.
AlphAI scores every news story that mentions TCRT with an AI model for sentiment and relevance, and aggregates insider trades from Alaunos Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alaunos Therapeutics (TCRT) will report Q3'26 earnings on November 17. Analysts expect an EPS of -2.05 USD. Revenue figures will also be disclosed.
Alaunos Therapeutics (TCRT) regained compliance with Nasdaq's $2.5M stockholders' equity requirement, avoiding delisting. The company completed a private placement financing on October 14, 2026, which Nasdaq confirmed restored compliance. The delisting hearing scheduled for November 10, 2026, was canceled. Alaunos still faces risks related to equity, stockholder approvals, and future compliance.
Alaunos Therapeutics, Inc. (TCRT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in comp
Fairmount Funds Management LLC disclosed a 19.99% stake in Alaunos Therapeutics, Inc. (TCRT) through a Schedule 13D filing. The investment includes preferred-share rights and potential board changes, with Fairmount designees set to fill three of five board seats upon shareholder approval. The stake is capped at 19.99% and will reduce to 9.99% if ownership falls below 9%. Fairmount backed Alaunos's merger with Velaris and a $350 million financing.
Alaunos Therapeutics (TCRT) stock surged 146.67% to $2.59 on news of acquiring Velaris Therapeutics and a $350M private placement. The acquisition expands Alaunos' pipeline with therapies for pulmonary arterial hypertension and related conditions. The company expects financial runway into 2029, with proof-of-concept data for VLR199 anticipated in 2028.
Alaunos Therapeutics, Inc. (TCRT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Transaction & Corporate Overview October 2026 Confidential Disclaimers and forward-looking statements Disclaimer This presentation has been prepared by Velaris Therapeutics, Inc. (“Velaris” or the “Company”). The information contained herein is provided as of the date hereof, is
Paragon Labs added former Apogee executives to its leadership team. Alaunos Therapeutics (TCRT) acquired Velaris Therapeutics, a biotech company focused on pulmonary hypertension therapies. Velaris is the ninth company launched around Paragon-discovered assets. Alaunos completed the acquisition, expanding its portfolio of ActRII-Fc ligand traps and biologics.
Alaunos Therapeutics (TCRT) received a delisting notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement. The company plans to request a hearing to contest the delisting.
Alaunos Therapeutics, Inc. (TCRT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules FORT LAUDERDALE, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced that it has entered into definitive agreements wi
Alaunos Therapeutics (TCRT) raised $1.12M via a registered direct offering of 380,469 shares and pre-funded warrants at $1.46 per share. Proceeds will fund working capital and corporate purposes. The offering is expected to close on or around September 21, 2026. TCRT stock closed at $1.60 on Thursday, up 25.00%, and was at $1.44 in pre-market trading, down 8.13%.